Artiva Biotherapeutics, Inc. 4

Director Elizabeth L. Hougen was granted a stock option for 16,250 shares of Artiva Biotherapeutics, Inc. common stock at a $10.42 exercise price as director compensation.

On September 10, 2026, director Elizabeth L. Hougen received a grant of a stock option to purchase 16,250 shares of Artiva Biotherapeutics, Inc. common stock at an exercise price of $10.42 per share, with the option scheduled to vest in full on the earlier of September 10, 2027 or the company’s 2027 annual stockholder meeting. This is a compensatory director stock option award rather than an open‑market purchase or sale, and following the grant she holds 16,250 derivative securities linked to the company’s common stock. Based on the stated exercise price, the notional value of the option grant is approximately $169,325, and the estimated value of her post‑transaction derivative holdings is inferred from the same price context.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-390534

Alert Tier

5